Advanced

Novel functional proteins coded by the human genome discovered in metastases of melanoma patients

Sanchez, Aniel LU ; Kuras, Magdalena LU ; Murillo, Jimmy Rodriguez LU ; Pla, Indira LU ; Pawlowski, Krzysztof LU ; Szasz, A. Marcell ; Gil, Jeovanis LU ; Nogueira, Fábio C.S. ; Perez-Riverol, Yasset and Eriksson, Jonatan LU , et al. (2019) In Cell Biology and Toxicology
Abstract

In the advanced stages, malignant melanoma (MM) has a very poor prognosis. Due to tremendous efforts in cancer research over the last 10 years, and the introduction of novel therapies such as targeted therapies and immunomodulators, the rather dark horizon of the median survival has dramatically changed from under 1 year to several years. With the advent of proteomics, deep-mining studies can reach low-abundant expression levels. The complexity of the proteome, however, still surpasses the dynamic range capabilities of current analytical techniques. Consequently, many predicted protein products with potential biological functions have not yet been verified in experimental proteomic data. This category of ‘missing proteins’ (MP) is... (More)

In the advanced stages, malignant melanoma (MM) has a very poor prognosis. Due to tremendous efforts in cancer research over the last 10 years, and the introduction of novel therapies such as targeted therapies and immunomodulators, the rather dark horizon of the median survival has dramatically changed from under 1 year to several years. With the advent of proteomics, deep-mining studies can reach low-abundant expression levels. The complexity of the proteome, however, still surpasses the dynamic range capabilities of current analytical techniques. Consequently, many predicted protein products with potential biological functions have not yet been verified in experimental proteomic data. This category of ‘missing proteins’ (MP) is comprised of all proteins that have been predicted but are currently unverified. As part of the initiative launched in 2016 in the USA, the European Cancer Moonshot Center has performed numerous deep proteomics analyses on samples from MM patients. In this study, nine MPs were clearly identified by mass spectrometry in MM metastases. Some MPs significantly correlated with proteins that possess identical PFAM structural domains; and other MPs were significantly associated with cancer-related proteins. This is the first study to our knowledge, where unknown and novel proteins have been annotated in metastatic melanoma tumour tissue.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Biobank, Mass spectrometry, Melanoma, Missing proteins, Proteomics, Tissue
in
Cell Biology and Toxicology
publisher
Springer
external identifiers
  • pmid:31599373
  • scopus:85074499088
ISSN
0742-2091
DOI
10.1007/s10565-019-09494-4
language
English
LU publication?
yes
id
abab915e-a2f4-415f-bd1d-e6e433d4a2d3
date added to LUP
2019-11-21 14:49:11
date last changed
2019-11-25 09:35:49
@article{abab915e-a2f4-415f-bd1d-e6e433d4a2d3,
  abstract     = {<p>In the advanced stages, malignant melanoma (MM) has a very poor prognosis. Due to tremendous efforts in cancer research over the last 10 years, and the introduction of novel therapies such as targeted therapies and immunomodulators, the rather dark horizon of the median survival has dramatically changed from under 1 year to several years. With the advent of proteomics, deep-mining studies can reach low-abundant expression levels. The complexity of the proteome, however, still surpasses the dynamic range capabilities of current analytical techniques. Consequently, many predicted protein products with potential biological functions have not yet been verified in experimental proteomic data. This category of ‘missing proteins’ (MP) is comprised of all proteins that have been predicted but are currently unverified. As part of the initiative launched in 2016 in the USA, the European Cancer Moonshot Center has performed numerous deep proteomics analyses on samples from MM patients. In this study, nine MPs were clearly identified by mass spectrometry in MM metastases. Some MPs significantly correlated with proteins that possess identical PFAM structural domains; and other MPs were significantly associated with cancer-related proteins. This is the first study to our knowledge, where unknown and novel proteins have been annotated in metastatic melanoma tumour tissue.</p>},
  author       = {Sanchez, Aniel and Kuras, Magdalena and Murillo, Jimmy Rodriguez and Pla, Indira and Pawlowski, Krzysztof and Szasz, A. Marcell and Gil, Jeovanis and Nogueira, Fábio C.S. and Perez-Riverol, Yasset and Eriksson, Jonatan and Appelqvist, Roger and Miliotis, Tasso and Kim, Yonghyo and Baldetorp, Bo and Ingvar, Christian and Olsson, Håkan and Lundgren, Lotta and Ekedahl, Henrik and Horvatovich, Peter and Sugihara, Yutaka and Welinder, Charlotte and Wieslander, Elisabet and Kwon, Ho Jeong and Domont, Gilberto B. and Malm, Johan and Rezeli, Melinda and Betancourt, Lazaro Hiram and Marko-Varga, György},
  issn         = {0742-2091},
  language     = {eng},
  month        = {10},
  publisher    = {Springer},
  series       = {Cell Biology and Toxicology},
  title        = {Novel functional proteins coded by the human genome discovered in metastases of melanoma patients},
  url          = {http://dx.doi.org/10.1007/s10565-019-09494-4},
  doi          = {10.1007/s10565-019-09494-4},
  year         = {2019},
}